drugset / Trial / NCT02151760
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
Phase 1
Completed
37 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This study is being done to determine the safety, biodistribution, and radiation dosimetry of 18F-DCFPyL, and to detect prostate cancer by visual analysis.
Timeline
- Start
- 2014-05
- Primary completion
- 2020-04
- Completion
- 2020-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-DCFPyL | Diagnostic / imaging agent | 331 mbq | Intravenous |